Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Compare

1,200 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RARE Analyst Ratings

Strong Buy

17 Buy

1 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Ultragenyx

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RARE Stock 12 Month Forecast

Average Price Target

$60.31

▲(143.20% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $60.31 with a high forecast of $120.00 and a low forecast of $23.00. The average price target represents a 143.20% change from the last price of $24.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","121":"$121","46.75":"$46.8","71.5":"$71.5","96.25":"$96.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.3125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,46.75,71.5,96.25,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.76,32.08615384615385,39.41230769230769,46.738461538461536,54.06461538461538,61.39076923076922,68.71692307692308,76.04307692307692,83.36923076923077,90.69538461538461,98.02153846153846,105.3476923076923,112.67384615384616,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.76,27.494807692307695,30.229615384615386,32.964423076923076,35.699230769230766,38.434038461538464,41.168846153846154,43.903653846153844,46.63846153846154,49.373269230769225,52.10807692307692,54.84288461538462,57.5776923076923,{"y":60.3125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.76,24.624615384615385,24.48923076923077,24.353846153846156,24.21846153846154,24.083076923076923,23.947692307692307,23.812307692307694,23.676923076923078,23.54153846153846,23.406153846153845,23.270769230769233,23.135384615384616,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":43.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.97,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$60.31

Lowest Price Target$23.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram Selvaraju

H.C. Wainwright

$60

Buy

141.94%

Upside

Reiterated

02/03/26

Ultragenyx: Advancing Rare Disease Pipeline, Key 2026–2027 Catalysts, and Path to Profitability Support Buy Rating

Maxwell Skor

Morgan Stanley

$50

Buy

101.61%

Upside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Pfizer (NYSE: PFE)

Tazeen Ahmad

Bank of America Securities

$57

Buy

129.84%

Upside

Reiterated

01/30/26

Bank of America Securities Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Eliana Merle

Barclays

$44

Buy

77.42%

Upside

Reiterated

01/27/26

Ultragenyx assumed with an Overweight at BarclaysUltragenyx assumed with an Overweight at Barclays

Benjamin Burnett

Wells Fargo

$45

Buy

81.45%

Upside

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (NASDAQ: ACRV), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Teva Pharmaceutical (NYSE: TEVA)

Joseph Schwartz

Leerink Partners

Buy

―

Reiterated

01/13/26

Ultragenyx Pharmaceutical (RARE) Gets a Buy from Leerink Partners

Laura Chico

Wedbush

$35→$23

Hold

-7.26%

Downside

Reiterated

01/13/26

Wedbush Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)

Yaron Werber

TD Cowen

$75

Buy

202.42%

Upside

Reiterated

01/12/26

TD Cowen Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)

Sami Corwin

William Blair

Buy

―

Reiterated

01/12/26

Ultragenyx: Better‑Than‑Expected Revenue, Strengthened Liquidity, and Upcoming Pipeline Catalysts Support Maintained Buy Rating

Luca Issi

RBC Capital

$72→$35

Buy

41.13%

Upside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Inogen (NASDAQ: INGN), Exelixis (NASDAQ: EXEL) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Yigal Nochomovitz

Citi

$50

Buy

101.61%

Upside

Reiterated

01/05/26

Citi Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Debjit Chattopadhyay

Guggenheim

$64→$52

Buy

109.68%

Upside

Reiterated

01/02/26

Ultragenyx price target lowered to $52 from $64 at GuggenheimUltragenyx price target lowered to $52 from $64 at Guggenheim

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$114→$63

Buy

154.03%

Upside

Reiterated

12/29/25

Jefferies Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Joon Lee

Truist Financial

$90

Buy

262.90%

Upside

Reiterated

12/29/25

Ultragenyx: Refocusing on Apazunersen and Strengthened Balance Sheet Support Buy Rating Despite OI Setback

Kristen Kluska

Cantor Fitzgerald

$105→$84

Buy

238.71%

Upside

Reiterated

12/29/25

Ultragenyx price target lowered to $84 from $105 at Cantor FitzgeraldUltragenyx price target lowered to $84 from $105 at Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram Selvaraju

H.C. Wainwright

$60

Buy

141.94%

Upside

Reiterated

02/03/26

Ultragenyx: Advancing Rare Disease Pipeline, Key 2026–2027 Catalysts, and Path to Profitability Support Buy Rating

Maxwell Skor

Morgan Stanley

$50

Buy

101.61%

Upside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Pfizer (NYSE: PFE)

Tazeen Ahmad

Bank of America Securities

$57

Buy

129.84%

Upside

Reiterated

01/30/26

Bank of America Securities Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Eliana Merle

Barclays

$44

Buy

77.42%

Upside

Reiterated

01/27/26

Ultragenyx assumed with an Overweight at BarclaysUltragenyx assumed with an Overweight at Barclays

Benjamin Burnett

Wells Fargo

$45

Buy

81.45%

Upside

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (NASDAQ: ACRV), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Teva Pharmaceutical (NYSE: TEVA)

Joseph Schwartz

Leerink Partners

Buy

―

Reiterated

01/13/26

Ultragenyx Pharmaceutical (RARE) Gets a Buy from Leerink Partners

Laura Chico

Wedbush

$35→$23

Hold

-7.26%

Downside

Reiterated

01/13/26

Wedbush Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)

Yaron Werber

TD Cowen

$75

Buy

202.42%

Upside

Reiterated

01/12/26

TD Cowen Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)

Sami Corwin

William Blair

Buy

―

Reiterated

01/12/26

Ultragenyx: Better‑Than‑Expected Revenue, Strengthened Liquidity, and Upcoming Pipeline Catalysts Support Maintained Buy Rating

Luca Issi

RBC Capital

$72→$35

Buy

41.13%

Upside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Inogen (NASDAQ: INGN), Exelixis (NASDAQ: EXEL) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Yigal Nochomovitz

Citi

$50

Buy

101.61%

Upside

Reiterated

01/05/26

Citi Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Debjit Chattopadhyay

Guggenheim

$64→$52

Buy

109.68%

Upside

Reiterated

01/02/26

Ultragenyx price target lowered to $52 from $64 at GuggenheimUltragenyx price target lowered to $52 from $64 at Guggenheim

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$114→$63

Buy

154.03%

Upside

Reiterated

12/29/25

Jefferies Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Joon Lee

Truist Financial

$90

Buy

262.90%

Upside

Reiterated

12/29/25

Ultragenyx: Refocusing on Apazunersen and Strengthened Balance Sheet Support Buy Rating Despite OI Setback

Kristen Kluska

Cantor Fitzgerald

$105→$84

Buy

238.71%

Upside

Reiterated

12/29/25

Ultragenyx price target lowered to $84 from $105 at Cantor FitzgeraldUltragenyx price target lowered to $84 from $105 at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ultragenyx Pharmaceutical

3 Months

xxx

Success Rate

13/22 ratings generated profit

Average Return

+1.74%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 59.09% of your transactions generating a profit, with an average return of +1.74% per trade.

1 Year

Whitney IjemCanaccord Genuity

Success Rate

5/13 ratings generated profit

Average Return

-8.91%

a rating ―

Copying Whitney Ijem's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -8.91% per trade.

2 Years

xxx

Success Rate

11/32 ratings generated profit

Average Return

-0.19%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 34.38% of your transactions generating a profit, with an average return of -0.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RARE Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RARE has received 32 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. RARE average Analyst price target in the past 3 months is 60.31.

Each month's total comprises the sum of three months' worth of ratings.

RARE Financial Forecast

RARE Earnings Forecast

Next quarter’s earnings estimate for RARE is -$1.10 with a range of -$1.76 to -$0.62. The previous quarter’s EPS was -$1.81. RARE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.

RARE Sales Forecast

Next quarter’s sales forecast for RARE is $197.50M with a range of $181.45M to $220.26M. The previous quarter’s sales results were $159.93M. RARE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.

RARE Stock Forecast FAQ

What is RARE’s average 12-month price target, according to analysts?

Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is 60.31.

What is RARE’s upside potential, based on the analysts’ average price target?

Ultragenyx Pharmaceutical has 143.20% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RARE a Buy, Sell or Hold?

Ultragenyx Pharmaceutical has a consensus rating of Strong Buy which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.

What is Ultragenyx Pharmaceutical’s price target?

The average price target for Ultragenyx Pharmaceutical is 60.31. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $23.00. The average price target represents 143.20% Increase from the current price of $24.8.

What do analysts say about Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of RARE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

RARE Analyst Ratings

RARE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ultragenyx Pharmaceutical

RARE Analyst Recommendation Trends

RARE Financial Forecast

RARE Earnings Forecast

RARE Sales Forecast

RARE Stock Forecast FAQ

Detailed List of Analyst Forecasts